Abstract
In a large community-randomized trial, biannual azithromycin distributions significantly reduced postneonatal childhood mortality in sub-Saharan African sites. Here, we present a prespecified secondary analysis showing that much of the protective effect was in the first 3 months postdistribution. Distributing more frequently than biannually could be considered if logistically feasible. Clinical Trials Registration. NCT02047981.
Highlights
In those children who died, we compared the distribution of time of death posttreatment in the 2 arms, and separately the season of treatment and the season of death
In the MORDOR trial, the hazard for death in children aged 1–59 months in the time after distribution was significantly lower in communities randomized to azithromycin compared to placebo
This confirmation of the trial results is not surprising as the analysis was similar in principle to the primary outcome where mortality was reduced 14%, estimated by negative binomial regression
Summary
In those children who died, we compared the distribution of time of death posttreatment in the 2 arms, and separately the season of treatment and the season of death. The MORDOR trial (Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance) found that azithromycin distributions significantly reduced postneonatal childhood mortality by 14% across sites in Malawi, Niger, and Tanzania [10].
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call